Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics, Inhaltsverzeichnis CC BY 4.0 · Rev Bras Ginecol Obstet 2020; 42(07): 438-443DOI: 10.1055/s-0040-1715547 Febrasgo Position Statement Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil Adnexal mass: diagnosis and management Number 1 - July 2020 Jesus Paula Carvalho Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil. , Renato Moretti-Marques Hospital Israelita Albert Einstein, São Paulo, SP, Brazil. , Agnaldo Lopes da Silva Filho Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. › Institutsangaben Artikel empfehlen Abstract Volltext Referenzen References 1 American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Gynecology. Practice Bulletin No. 174: evaluation and management of adnexal masses. Obstet Gynecol 2016; 128 (05) e210-e226 . Doi: 10.1097/AOG.0000000000001768 2 Lima RA, Viotti LV, Cândido EB, Silva-Filho FL. Abordagem das massas anexiais com suspeita de câncer de ovário. Femina 2010; 38 (06) 259-262 3 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Ovarian Cancer including fallopian tube cancer and primary peritoneal cancer [Internet]. Version 1.2020. 2010 [cited 2020 Mar 11]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx#ovarian 4 Woo YL, Kyrgiou M, Bryant A, Everett T, Dickinson HO. Centralisation of services for gynaecological cancers - a Cochrane systematic review. Gynecol Oncol 2012; 126 (02) 286-290 . Doi: 10.1016/j.ygyno.2012.04.012 5 Royal College of Obstetricians and Gynaecologists. The management ovarian cysts in postmenopausal women. London: RCOG; 2016 6 Royal College of Obstetricians and Gynaecologists. Ovarian masses in premenopausal women, management of suspected. London: RCOG; 2011 7 American College of Radiology. Don’t recommend follow-up imaging for clinically inconsequential adnexal cysts [Internet]. 2012 [cited 2019 Dec 12]. Available from: https://www.choosingwisely.org/clinician-lists/american-college-radiology-follow-up-imaging-for-adnexal-cysts/ 8 Graffeo R, Livraghi L, Pagani O, Goldhirsch A, Partridge AH, Garber JE. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Breast Cancer Res Treat 2016; 160 (03) 393-410 . Doi: 10.1007/s10549-016-4003-9 9 Ring KL, Garcia C, Thomas MH, Modesitt SC. Current and future role of genetic screening in gynecologic malignancies. Am J Obstet Gynecol 2017; 217 (05) 512-521 . Doi: 10.1016/j.ajog.2017.04.011 10 Ebell MH, Culp MB, Radke TJ. A systematic review of symptoms for the diagnosis of ovarian cancer. Am J Prev Med 2016; 50 (03) 384-394 . Doi: 10.1016/j.amepre.2015.09.023 11 Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004; 291 (022) 2705-2712 . Doi: 10.1001/jama.291.22.2705 12 Dodge JE, Covens AL, Lacchetti C, Elit LM, Le T, Devries-Aboud M. , et al. Management of a suspicious adnexal mass: a clinical practice guideline. Curr Oncol 2012; 19 (04) e244-e257 . Doi: 10.3747/co.19.980 13 Timmerman D, Van Calster B, Testa A, Savelli L, Fischerova D, Froyman W. . et al. Predicting the risk of malignancy in adnexal masses based on the simple rules from the International Ovarian Tumor Analysis group. Am J Obstet Gynecol 2016; 214 (04) 424-437 . Doi: 10.1016/j.ajog.2016.01.007 14 Sayasneh A, Ferrara L, De Cock B, Saso S, Al-Memar M, Johnson S. , et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model: a multicentre external validation study. Br J Cancer 2016; 115 (05) 542-548 . Doi: 10.1038/bjc.2016.227 15 Abramowicz JS, Timmerman D. Ovarian mass-differentiating benign from malignant: the value of the International Ovarian Tumor Analysis ultrasound rules. Am J Obstet Gynecol 2017; 217 (06) 652-660 . Doi: 10.1016/j.ajog.2017.07.019 16 Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001; 276 (029) 27371-27375 . Doi: 10.1074/jbc.M103554200 17 Sehouli J, Akdogan Z, Heinze T, Könsgen D, Stengel D, Mustea A. , et al. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study. Anticancer Res 2003; 23 (2A): 1115-1118 18 Jacobs I, Bast Jr. RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989; 4 (01) 1-12 . Doi: 10.1093/oxfordjournals.humrep.a136832 19 Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H. , et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009; 100 (08) 1315-1319 . Doi: 10.1038/sj.bjc.6605011 20 Anastasi E, Granato T, Falzarano R, Storelli P, Ticino A, Frati L. , et al. The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer. J Ovarian Res 2013; 6: 44 . Doi: 10.1186/1757-2215-6-44 21 Hallamaa M, Suvitie P, Huhtinen K, Matomäki J, Poutanen M, Perheentupa A. Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women. Gynecol Oncol 2012; 125 (03) 667-672 . Doi: 10.1016/j.ygyno.2012.03.011 22 Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990; 97 (010) 922-929 . Doi: 10.1111/j.1471-0528.1990.tb02448.x 23 Chudecka-Glaz AM. ROMA, an algorithm for ovarian cancer. Clin Chim Acta 2015; 440: 143-151 . Doi: 10.1016/j.cca.2014.11.015 24 Anton C, Carvalho FM, Oliveira EI, Maciel GAR, Baracat EC, Carvalho JP. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics (Sao Paulo) 2012; 67 (05) 437-441 . Doi: 10.6061/clinics/2012(05)06 25 Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ. , et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112 (01) 40-46 . Doi: 10.1016/j.ygyno.2008.08.031 26 Hermans AJ, Kluivers KB, Janssen LM, Siebers AG, Wijnen MHWA, Bulten J. , et al. Adnexal masses in children, adolescents and women of reproductive age in the Netherlands: a nationwide population-based cohort study. Gynecol Oncol 2016; 143 (01) 93-97 . Doi: 10.1016/j.ygyno.2016.07.096 27 Reddihalli PV, Subbian A, Umadevi K, Rathod PS, Krishnappa S, Nanaiah SP. , et al. Immature teratoma of ovary--outcome following primary and secondary surgery: study of a single institution cohort. Eur J Obstet Gynecol Reprod Biol 2015; 192: 17-21 . Doi: 10.1016/j.ejogrb.2015.06.017 28 Aslam MF, Ghayoori R, Khulpateea N. Adnexal masses: relative accuracy of sonography and frozen section in predicting final pathology. J Obstet Gynaecol 2010; 30 (02) 187-189 . Doi: 10.3109/01443610903461444 29 Kotsopoulos J, Narod SA. Prophylactic salpingectomy for the prevention of ovarian cancer: who should we target?. Int J Cancer 2020; Feb 9 [ahead of print] 30 Kurman R, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34 (03) 433-443 . Doi: 10.1097/PAS.0b013e3181cf3d79 31 Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol 2011; 42 (07) 918-931 . Doi: 10.1016/j.humpath.2011.03.003 32 Diniz PM, Carvalho JP, Baracat EC, Carvalho FM. Fallopian tube origin of supposed ovarian high-grade serous carcinomas. Clinics (Sao Paulo) 2011; 66 (01) 73-76 . Doi: 10.1590/S1807-59322011000100013 33 Carvalho JP, Baracat EC, Carvalho FM. Ovarian cancer previvors: how to manage these patients?. Clinics (Sao Paulo) 2019; 74: e1343 . Doi: 10.6061/clinics/2019/e1343 34 Urban RR, He H, Alfonso R, Hardesty MM, Gray HJ, Goff BA. Ovarian cancer outcomes: predictors of early death. Gynecol Oncol 2016; 140 (03) 474-480 . Doi: 10.1016/j.ygyno.2015.12.021 35 Erickson BK, Martin JY, Shah MM, Straughn Jr JM. Leath CA 3rd. Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center. Gynecol Oncol 2014; 133 (02) 142-146 . Doi: 10.1016/j.ygyno.2014.02.006 36 Dahm-Kähler P, Palmqvist C, Staf C, Holmberg E, Johannesson L. Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study. Gynecol Oncol 2016; 142 (02) 211-216 . Doi: 10.1016/j.ygyno.2016.05.025 37 Casarin J, Laganà AS, Uccella S, Cromi A, Pinelli C, Gisone B. , et al. Surgical treatment of large adnexal masses: a retrospective analysis of 330 consecutive cases. Minim Invasive Ther Allied Technol 2019; Aug 2 [ahead of print] 38 Medeiros LRF, Rosa DD, Bozzetti MC, Fachel JMG, Furness S, Garry R. , et al. Laparoscopy versus laparotomy for benign ovarian tumour. Cochrane Database Syst Rev 2009; (002) CD004751 . Doi: 10.1002/14651858.CD004751.pub3 39 Ratnavelu ND, Brown AP, Mallett S, Scholten RJPM, Patel A, Founta C. , et al. Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses. Cochrane Database Syst Rev 2016; (003) CD010360 . Doi: 10.1002/14651858.CD010360.pub2
